Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Raw Materials (2022 - 2025)

InMed Pharmaceuticals' Raw Materials history spans 4 years, with the latest figure at $172200.0 for Q3 2025.

  • For Q3 2025, Raw Materials fell 37.26% year-over-year to $172200.0; the TTM value through Sep 2025 reached $172200.0, down 37.26%, while the annual FY2025 figure was $258300.0, 30.69% down from the prior year.
  • Raw Materials reached $172200.0 in Q3 2025 per INM's latest filing, down from $258300.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $387071.0 in Q1 2023 to a low of $172200.0 in Q4 2024.
  • Average Raw Materials over 4 years is $250874.9, with a median of $233518.5 recorded in 2022.
  • The largest YoY upside for Raw Materials was 78.55% in 2024 against a maximum downside of 49.23% in 2024.
  • A 4-year view of Raw Materials shows it stood at $208737.0 in 2022, then changed by 0.0% to $208737.0 in 2023, then dropped by 17.5% to $172200.0 in 2024, then changed by 0.0% to $172200.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Raw Materials are $172200.0 (Q3 2025), $258300.0 (Q2 2025), and $258300.0 (Q1 2025).